 Stephen Frankel
Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Fibrosis | 8 | 2011 | 399 | 1.120 |
Why?
| | Vasculitis | 3 | 2012 | 67 | 0.780 |
Why?
| | Lung Diseases | 5 | 2012 | 782 | 0.710 |
Why?
| | Idiopathic Pulmonary Fibrosis | 6 | 2015 | 657 | 0.610 |
Why?
| | Hospital Mortality | 2 | 2014 | 920 | 0.580 |
Why?
| | Critical Illness | 3 | 2017 | 836 | 0.530 |
Why?
| | Lung Diseases, Interstitial | 9 | 2015 | 651 | 0.490 |
Why?
| | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 2 | 2012 | 23 | 0.430 |
Why?
| | Churg-Strauss Syndrome | 5 | 2018 | 27 | 0.360 |
Why?
| | Hospitals, Veterans | 1 | 2012 | 255 | 0.350 |
Why?
| | Arteritis | 1 | 2010 | 27 | 0.330 |
Why?
| | Cause of Death | 1 | 2012 | 433 | 0.330 |
Why?
| | Wounds and Injuries | 2 | 2017 | 834 | 0.320 |
Why?
| | Fibroblasts | 5 | 2011 | 1002 | 0.320 |
Why?
| | Eosinophilia | 1 | 2011 | 218 | 0.300 |
Why?
| | Respiration, Artificial | 2 | 2017 | 670 | 0.300 |
Why?
| | Respiratory Tract Diseases | 1 | 2010 | 181 | 0.290 |
Why?
| | Alveolitis, Extrinsic Allergic | 1 | 2008 | 97 | 0.270 |
Why?
| | Granulomatosis with Polyangiitis | 4 | 2018 | 45 | 0.270 |
Why?
| | Intensive Care Units | 1 | 2014 | 871 | 0.270 |
Why?
| | Colitis, Ischemic | 1 | 2007 | 6 | 0.270 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2009 | 172 | 0.270 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2007 | 28 | 0.270 |
Why?
| | Escherichia coli O157 | 1 | 2007 | 34 | 0.270 |
Why?
| | Escherichia coli Infections | 1 | 2007 | 115 | 0.250 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2004 | 324 | 0.240 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2005 | 166 | 0.230 |
Why?
| | Venous Thromboembolism | 1 | 2009 | 324 | 0.230 |
Why?
| | Exercise Therapy | 1 | 2009 | 440 | 0.230 |
Why?
| | Connective Tissue Diseases | 3 | 2013 | 85 | 0.220 |
Why?
| | Apoptosis | 4 | 2011 | 2551 | 0.210 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2005 | 1244 | 0.200 |
Why?
| | Spike Glycoprotein, Coronavirus | 2 | 2022 | 119 | 0.200 |
Why?
| | Antiviral Agents | 2 | 2021 | 733 | 0.200 |
Why?
| | Precancerous Conditions | 1 | 2004 | 165 | 0.200 |
Why?
| | Lung | 6 | 2014 | 4103 | 0.190 |
Why?
| | Adenoma | 1 | 2004 | 223 | 0.190 |
Why?
| | Smoking | 1 | 2009 | 1610 | 0.180 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2022 | 814 | 0.180 |
Why?
| | Humans | 34 | 2022 | 138969 | 0.170 |
Why?
| | Hypertension, Pulmonary | 2 | 2009 | 1924 | 0.170 |
Why?
| | Mycophenolic Acid | 2 | 2013 | 117 | 0.150 |
Why?
| | Diagnosis, Differential | 4 | 2011 | 1482 | 0.150 |
Why?
| | Biomarkers | 1 | 2010 | 4095 | 0.150 |
Why?
| | fas Receptor | 2 | 2011 | 97 | 0.140 |
Why?
| | Ganciclovir | 1 | 2017 | 53 | 0.140 |
Why?
| | Interferon-gamma | 2 | 2013 | 787 | 0.130 |
Why?
| | Cytomegalovirus | 1 | 2017 | 162 | 0.130 |
Why?
| | Aged | 13 | 2017 | 24172 | 0.120 |
Why?
| | Mutation | 3 | 2022 | 3984 | 0.120 |
Why?
| | Cytomegalovirus Infections | 1 | 2017 | 195 | 0.120 |
Why?
| | Middle Aged | 14 | 2018 | 33782 | 0.120 |
Why?
| | Tomography, X-Ray Computed | 5 | 2015 | 2697 | 0.110 |
Why?
| | Survival Rate | 4 | 2015 | 1934 | 0.110 |
Why?
| | Male | 17 | 2017 | 68250 | 0.110 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 96 | 0.100 |
Why?
| | Interleukin-6 | 1 | 2017 | 785 | 0.100 |
Why?
| | Physical Therapy Modalities | 1 | 2016 | 308 | 0.100 |
Why?
| | Immunosuppressive Agents | 2 | 2018 | 848 | 0.100 |
Why?
| | Female | 16 | 2018 | 74015 | 0.090 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 1 | 2011 | 11 | 0.090 |
Why?
| | Hypereosinophilic Syndrome | 1 | 2011 | 9 | 0.090 |
Why?
| | Pulmonary Eosinophilia | 1 | 2011 | 27 | 0.090 |
Why?
| | Pulmonary Alveoli | 2 | 2011 | 408 | 0.090 |
Why?
| | Immunologic Factors | 1 | 2013 | 243 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2004 | 2533 | 0.090 |
Why?
| | Respiratory Insufficiency | 2 | 2017 | 326 | 0.090 |
Why?
| | Sepsis | 1 | 2017 | 611 | 0.090 |
Why?
| | Rheumatic Diseases | 1 | 2011 | 83 | 0.080 |
Why?
| | Bronchoscopy | 1 | 2011 | 225 | 0.080 |
Why?
| | Biopsy | 2 | 2014 | 1072 | 0.080 |
Why?
| | Antibodies, Antinuclear | 1 | 2009 | 68 | 0.080 |
Why?
| | Follow-Up Studies | 4 | 2017 | 5152 | 0.080 |
Why?
| | CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2009 | 21 | 0.080 |
Why?
| | Amino Acyl-tRNA Synthetases | 1 | 2009 | 30 | 0.080 |
Why?
| | Antibodies, Neutralizing | 2 | 2022 | 302 | 0.080 |
Why?
| | Idiopathic Interstitial Pneumonias | 1 | 2009 | 45 | 0.080 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2013 | 357 | 0.070 |
Why?
| | Pulmonary Diffusing Capacity | 3 | 2015 | 78 | 0.070 |
Why?
| | Up-Regulation | 1 | 2011 | 852 | 0.070 |
Why?
| | Disease Progression | 2 | 2015 | 2752 | 0.070 |
Why?
| | Fatal Outcome | 1 | 2008 | 309 | 0.070 |
Why?
| | Respiratory Tract Infections | 1 | 2011 | 383 | 0.070 |
Why?
| | Survival Analysis | 1 | 2010 | 1311 | 0.060 |
Why?
| | Pericardium | 1 | 2007 | 56 | 0.060 |
Why?
| | Acute Lung Injury | 1 | 2010 | 299 | 0.060 |
Why?
| | Biopsy, Needle | 1 | 2007 | 187 | 0.060 |
Why?
| | Cells, Cultured | 4 | 2011 | 4182 | 0.060 |
Why?
| | Arthritis, Rheumatoid | 1 | 2015 | 1165 | 0.060 |
Why?
| | Prognosis | 3 | 2009 | 3995 | 0.060 |
Why?
| | Cysts | 1 | 2007 | 114 | 0.060 |
Why?
| | Anastomosis, Surgical | 1 | 2007 | 158 | 0.060 |
Why?
| | Colectomy | 1 | 2007 | 101 | 0.060 |
Why?
| | Comorbidity | 1 | 2011 | 1657 | 0.060 |
Why?
| | Rare Diseases | 1 | 2007 | 108 | 0.060 |
Why?
| | Scleroderma, Systemic | 1 | 2007 | 122 | 0.060 |
Why?
| | Autoantibodies | 1 | 2013 | 1457 | 0.060 |
Why?
| | Fas-Associated Death Domain Protein | 1 | 2005 | 9 | 0.060 |
Why?
| | Abdominal Pain | 1 | 2007 | 142 | 0.060 |
Why?
| | Antibodies, Antineutrophil Cytoplasmic | 1 | 2006 | 35 | 0.060 |
Why?
| | Acute Disease | 1 | 2008 | 993 | 0.060 |
Why?
| | Respiratory Function Tests | 3 | 2014 | 561 | 0.060 |
Why?
| | Lung Transplantation | 1 | 2008 | 313 | 0.060 |
Why?
| | Heart Rate | 1 | 2009 | 801 | 0.060 |
Why?
| | Wound Healing | 1 | 2008 | 345 | 0.060 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2005 | 83 | 0.060 |
Why?
| | Pleura | 1 | 2004 | 24 | 0.060 |
Why?
| | Colonoscopy | 1 | 2007 | 245 | 0.060 |
Why?
| | Proline | 1 | 2005 | 76 | 0.060 |
Why?
| | Protein Binding | 2 | 2021 | 2233 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 183 | 0.050 |
Why?
| | Hyperplasia | 1 | 2004 | 176 | 0.050 |
Why?
| | Walking | 1 | 2009 | 541 | 0.050 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2004 | 122 | 0.050 |
Why?
| | Retrospective Studies | 4 | 2010 | 15901 | 0.050 |
Why?
| | Vital Capacity | 2 | 2015 | 312 | 0.050 |
Why?
| | Echocardiography | 1 | 2007 | 638 | 0.050 |
Why?
| | Gene Expression | 2 | 2009 | 1487 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2004 | 214 | 0.050 |
Why?
| | Bleomycin | 1 | 2004 | 247 | 0.050 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 358 | 0.050 |
Why?
| | Polyarteritis Nodosa | 1 | 2002 | 7 | 0.050 |
Why?
| | Cohort Studies | 2 | 2015 | 5744 | 0.050 |
Why?
| | Immunohistochemistry | 1 | 2007 | 1730 | 0.050 |
Why?
| | Takayasu Arteritis | 1 | 2002 | 15 | 0.050 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2005 | 429 | 0.050 |
Why?
| | Kaplan-Meier Estimate | 2 | 2015 | 897 | 0.050 |
Why?
| | Incidence | 1 | 2009 | 2830 | 0.050 |
Why?
| | Severity of Illness Index | 2 | 2007 | 2849 | 0.050 |
Why?
| | Radiography | 1 | 2004 | 839 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2017 | 10921 | 0.050 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 132 | 0.050 |
Why?
| | Fibrosis | 1 | 2004 | 539 | 0.050 |
Why?
| | Intestinal Mucosa | 1 | 2007 | 620 | 0.050 |
Why?
| | Age Factors | 1 | 2009 | 3276 | 0.050 |
Why?
| | Immunity, Humoral | 1 | 2022 | 115 | 0.050 |
Why?
| | Antigen-Antibody Reactions | 1 | 2021 | 54 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2015 | 1497 | 0.040 |
Why?
| | Longitudinal Studies | 3 | 2014 | 2850 | 0.040 |
Why?
| | Macrophages, Alveolar | 1 | 2004 | 396 | 0.040 |
Why?
| | Surface Plasmon Resonance | 1 | 2021 | 88 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2010 | 7685 | 0.040 |
Why?
| | Molecular Docking Simulation | 1 | 2021 | 111 | 0.040 |
Why?
| | Forced Expiratory Volume | 2 | 2015 | 488 | 0.040 |
Why?
| | Receptors, Virus | 1 | 2021 | 94 | 0.040 |
Why?
| | Ligands | 1 | 2022 | 666 | 0.040 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 153 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2004 | 2171 | 0.040 |
Why?
| | Proportional Hazards Models | 2 | 2015 | 1281 | 0.040 |
Why?
| | Amino Acids | 1 | 2022 | 496 | 0.040 |
Why?
| | Pneumonia | 1 | 2004 | 644 | 0.040 |
Why?
| | Cell Line | 3 | 2011 | 2879 | 0.040 |
Why?
| | Kinetics | 1 | 2021 | 1649 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 370 | 0.030 |
Why?
| | Intention to Treat Analysis | 1 | 2017 | 76 | 0.030 |
Why?
| | Binding Sites | 1 | 2021 | 1317 | 0.030 |
Why?
| | Virus Activation | 1 | 2017 | 86 | 0.030 |
Why?
| | Mice | 4 | 2011 | 17827 | 0.030 |
Why?
| | Risk Factors | 1 | 2009 | 10385 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2018 | 475 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2022 | 2815 | 0.030 |
Why?
| | Mice, Inbred C3H | 2 | 2005 | 270 | 0.030 |
Why?
| | Adult | 4 | 2017 | 38393 | 0.030 |
Why?
| | Rituximab | 1 | 2013 | 202 | 0.020 |
Why?
| | Predictive Value of Tests | 2 | 2009 | 2030 | 0.020 |
Why?
| | Patient Dropouts | 1 | 2013 | 63 | 0.020 |
Why?
| | Microscopic Polyangiitis | 1 | 2012 | 12 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2017 | 1949 | 0.020 |
Why?
| | Length of Stay | 1 | 2017 | 1237 | 0.020 |
Why?
| | Animals | 4 | 2011 | 37242 | 0.020 |
Why?
| | Necrosis | 1 | 2012 | 248 | 0.020 |
Why?
| | Fas Ligand Protein | 1 | 2011 | 60 | 0.020 |
Why?
| | Cell Line, Transformed | 1 | 2011 | 145 | 0.020 |
Why?
| | Alanine-tRNA Ligase | 1 | 2009 | 4 | 0.020 |
Why?
| | Threonine-tRNA Ligase | 1 | 2009 | 5 | 0.020 |
Why?
| | Elastin | 1 | 2009 | 79 | 0.020 |
Why?
| | Myoblasts | 1 | 2009 | 82 | 0.020 |
Why?
| | Syndrome | 1 | 2009 | 377 | 0.020 |
Why?
| | Oximetry | 1 | 2009 | 118 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2009 | 522 | 0.020 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2007 | 67 | 0.020 |
Why?
| | Transfection | 1 | 2009 | 942 | 0.020 |
Why?
| | Collagen | 1 | 2009 | 459 | 0.020 |
Why?
| | Exercise Test | 1 | 2009 | 621 | 0.020 |
Why?
| | Medical Records | 1 | 2006 | 183 | 0.010 |
Why?
| | Consensus Sequence | 1 | 2005 | 73 | 0.010 |
Why?
| | Asparagine | 1 | 2005 | 30 | 0.010 |
Why?
| | NF-kappa B | 1 | 2009 | 678 | 0.010 |
Why?
| | COS Cells | 1 | 2005 | 183 | 0.010 |
Why?
| | Sequence Deletion | 1 | 2005 | 184 | 0.010 |
Why?
| | Serine | 1 | 2005 | 141 | 0.010 |
Why?
| | Cytoplasm | 1 | 2005 | 270 | 0.010 |
Why?
| | Growth Substances | 1 | 2004 | 148 | 0.010 |
Why?
| | Culture Media, Conditioned | 1 | 2004 | 112 | 0.010 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2005 | 376 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2011 | 1746 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2011 | 3029 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2004 | 150 | 0.010 |
Why?
| | Logistic Models | 1 | 2009 | 2093 | 0.010 |
Why?
| | Th2 Cells | 1 | 2004 | 178 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2009 | 1103 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2005 | 862 | 0.010 |
Why?
| | Cell Communication | 1 | 2004 | 316 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2004 | 442 | 0.010 |
Why?
| | Cell Membrane | 1 | 2005 | 716 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2009 | 2480 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2009 | 3574 | 0.010 |
Why?
| | Inflammation | 1 | 2012 | 2853 | 0.010 |
Why?
| | Cell Survival | 1 | 2004 | 1126 | 0.010 |
Why?
| | Proto-Oncogene Proteins | 1 | 2004 | 621 | 0.010 |
Why?
| | Phosphorylation | 1 | 2005 | 1767 | 0.010 |
Why?
| | Prospective Studies | 1 | 2011 | 7661 | 0.010 |
Why?
| | Young Adult | 1 | 2009 | 13371 | 0.010 |
Why?
| | Adolescent | 1 | 2009 | 21581 | 0.000 |
Why?
|
|
Frankel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|